Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski Sells 8,768 Shares

Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the transaction, the director now owns 356,605 shares of the company’s stock, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Exelixis Trading Up 2.8 %

NASDAQ EXEL opened at $38.69 on Friday. The stock’s 50 day moving average is $34.53 and its two-hundred day moving average is $31.62. The company has a market capitalization of $10.83 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $38.72.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

EXEL has been the topic of several analyst reports. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Exelixis in a research report on Thursday, February 13th. Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Piper Sandler lifted their price target on Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus raised their price objective on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.24.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB raised its position in shares of Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 290 shares during the last quarter. Balyasny Asset Management L.P. raised its position in shares of Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock valued at $573,000 after acquiring an additional 317 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of Exelixis by 4.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock valued at $235,000 after acquiring an additional 330 shares during the last quarter. Covestor Ltd raised its position in shares of Exelixis by 5.7% during the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 341 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its position in shares of Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after acquiring an additional 354 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.